Bausch Health will acquire DURECT for $63 million upfront, gaining rights to larsucosterol, a promising drug candidate for treating alcoholic hepatitis, with potential additional milestone payments of up to $350 million.

DURECT Corporation, a late-stage biopharmaceutical company, will report its fourth quarter and full year 2024 financial results and provide a business update on March 26, 2025. The company is pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury.

Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.

Durect (DRRX) delivered earnings and revenue surprises of -19.05% and 33.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

CARISMA THERAP (CARM) delivered earnings and revenue surprises of -24.32% and 12.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?